NeoGenomics is trading at $16.55, down 4.03%, amid broad market weakness; no clear company-specific announcement explaining the October 16 decline was identified. - The latest reported company news was an expanded Indica Labs partnership on October 15. - In the supplied market context, the S&P 500 was down 1.17% and the Nasdaq Composite was down 2.13%. - Healthcare strength was a counterpoint, with XLV up 2.12%; broader risk-off sentiment is the likeliest context, not a confirmed company catalyst.